CureC9 and BrainXell Partner to Advance ALS and FTD ResearchThrough Patient-Driven Innovation

What happens when patient advocacy, scientific research, and biotechnology come together? In this conversation, CureC9 Co-Founder Yentli Soto Albrecht, PhD, and BrainXell discuss a unique partnership that transforms patient-donated cells into commercially available human iPSC-derived disease models for ALS and FTD research. Learn how this collaboration is expanding access to human-relevant tools that empower researchers worldwide to better understand neurodegenerative disease and accelerate the discovery of new therapies. Learn more: https://curec9.com/projects/c9orf72-s... https://brainxell.com/